Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy

Autor: Hu, Shihe ^{a, b, c}, Jiang, Cuihua ^{a, b}, Jin, Qiaomei ^{a, b, ⁎}

Publikováno v: In European Journal of Medicinal Chemistry 5 April 2024 269

Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors

Autor: Ivana Malvacio, Alberto Cuzzolin, Mattia Sturlese, D. Mariano A. Vera, E. Laura Moyano, Stefano Moro

Publikováno v: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 33, Iss 1, Pp 171-183 (2018)

The serine-threonine checkpoint kinase 1 (Chk1) plays a critical role in the cell cycle arrest in response to DNA damage. In the last decade, Chk1 inhibitors have emerged as a novel therapeutic strategy to potentiate the anti-tumour efficacy of cytot

Externí odkaz: https://doaj.org/article/5f64f7eec8024ce68274172a772c8777

The Role of Chaperone-Mediated Autophagy in Cell Cycle Control and Its Implications in Cancer

Autor: Marina Andrade-Tomaz, Izadora de Souza, Clarissa Ribeiro Reily Rocha, Luciana Rodrigues Gomes

Publikováno v: Cells, Vol 9, Iss 9, p 2140 (2020)

The cell cycle involves a network of proteins that modulate the sequence and timing of proliferation events. Unregulated proliferation is the most fundamental hallmark of cancer; thus, changes in cell cycle control are at the heart of malignant trans

Externí odkaz: https://doaj.org/article/3e40159affb84bea823b715ae1bcc7c3

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

Autor: Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, van den Handel, Kim, van den Boogaard, Marlinde, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A.M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., van Hooff, Sander R., Afd Pharmaceutics, Pharmaceutics

Publikováno v: Frontiers in Oncology, 12, 1. Frontiers Media S.A.
Frontiers in Oncology, 12:929123. Frontiers Media S.A.
Frontiers in oncology, 12:929123. Frontiers Media S.A.
Keller, K M, Eleveld, T F, Schild, L, van den Handel, K, van den Boogaard, M, Amo-Addae, V, Eising, S, Ober, K, Koopmans, B, Looijenga, L, Tytgat, G A M, Ylstra, B, Molenaar, J J, Dolman, M E M & van Hooff, S R 2022, ' Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma ', Frontiers in Oncology, vol. 12, 929123 . https://doi.org/10.3389/fonc.2022.929123

Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss of chromosome 11q and MYCN amp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329aea7d7c7654768bccaddc20ad5c25
https://dspace.library.uu.nl/handle/1874/425877

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.